

# APPENDIX

**TABLE I**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**SELECTED CONSOLIDATED INFORMATION**  
(in millions, except per share amounts)  
(unaudited)

	Three Months Ended December 31, 2019									
<b>Consolidated</b>	<b>Net Sales</b>	<b>Gross Profit</b>	<b>R&amp;D Expense</b>	<b>DSG&amp;A Expense</b>	<b>Restructuring, Impairment Charges, and Other Operating Income</b>	<b>Operating Income (Loss)</b>	<b>Interest, Other, and Change in Financial Assets</b>	<b>Income Tax Expense (Benefit)</b>	<b>Net Income (Loss)**</b>	<b>Diluted Earnings (Loss) per Share**</b>
<b>Reported</b>	\$ 1,322.8	\$ 480.9	\$ 59.4	\$ 288.6	\$ 139.7	\$ (6.8)	\$ 27.4	\$ (15.2)	\$ (19.0)	\$ (0.14)
As a % of reported net sales		36.4%	4.5%	21.8%	10.6%	(0.5)%	2.1%	(1.2)%	(1.4)%	
Effective tax rate								44.5 %		
<i>Pre-tax adjustments:</i>										
Amortization expense related primarily to acquired intangible assets		\$ 48.8	\$ (0.1)	\$ (30.9)	\$ —	\$ 79.8	\$ —	\$ —	\$ 79.8	\$ 0.59
Acquisition and integration-related charges and contingent consideration adjustments		0.1	—	(1.0)	0.5	0.6	—	—	0.6	—
Impairment charges		—	—	—	(141.6)	141.6	—	—	141.6	1.03
(Gain) loss on divestitures		—	—	3.6	1.0	(4.6)	(0.7)	—	(3.9)	(0.03)
Unusual litigation		—	—	(1.8)	—	1.8	—	—	1.8	0.01
Restructuring charges and other termination benefits		—	—	—	0.4	(0.4)	—	—	(0.4)	—
Change in financial assets		—	—	—	—	—	3.6	—	(3.6)	(0.03)
(Gain) Loss on investment securities		—	—	—	—	—	4.0	—	(4.0)	(0.03)
Separation and reorganization expense		—	—	(2.2)	—	2.2	—	—	2.2	0.02
Non-GAAP tax adjustments*		—	—	—	—	—	—	50.3	(50.3)	(0.36)
<b>Adjusted</b>	\$ 529.8	\$ 59.3	\$ 256.3	\$ —	\$ 214.2	\$ 34.3	\$ 35.1	\$ 144.8	\$ 1.06	
As a % of reported net sales		40.1%	4.5%	19.4%		16.2 %	2.6%	2.7 %	10.9 %	
Effective tax rate								19.5 %		

**Diluted weighted average shares outstanding**

**Reported 137.0**

\*The non-GAAP tax adjustments are primarily due to: (1) \$4.9 million of tax effects of pretax non-GAAP adjustments that are calculated based upon the specific rate of the applicable jurisdiction of the pretax items and (2) \$43.8 million of valuation allowance releases in the U.S. and Australia.

\*\*Individual pre-tax line item adjustments have not been tax effected, as tax expense on these items are aggregated in the "Non-GAAP tax adjustments" line item.

**TABLE I (CONTINUED)**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**SELECTED CONSOLIDATED INFORMATION**  
(in millions, except per share amounts)  
(unaudited)

Three Months Ended December 31, 2018

<b>Consolidated</b>	<b>Net Sales</b>	<b>Gross Profit</b>	<b>R&amp;D Expense</b>	<b>DSG&amp;A Expense</b>	<b>Restructuring, Impairment Charges, and Other Operating Income</b>	<b>Operating Income</b>	<b>Interest, Other, and Change in Financial Assets</b>	<b>Income Tax Expense</b>	<b>Net Income**</b>	<b>Diluted Earnings per Share**</b>
<b>Reported</b>	<b>\$ 1,195.2</b>	<b>\$ 443.0</b>	<b>\$ 44.6</b>	<b>\$ 293.6</b>	<b>\$ (2.7)</b>	<b>\$ 107.5</b>	<b>\$ (96.2)</b>	<b>\$ 122.2</b>	<b>\$ 81.5</b>	<b>\$ 0.60</b>
As a % of reported net sales		37.1%	3.7%	24.6%	(0.2)%	9.0%	(8.0)%	10.2%	6.8%	
Effective tax rate								60.0%		
<i>Pre-tax adjustments:</i>										
Amortization expense primarily related to acquired intangible assets		\$ 47.4	\$ (0.2)	\$ (30.4)	\$ —	\$ 78.0	\$ —	\$ —	\$ 78.0	\$ 0.57
Acquisition and integration-related charges and contingent consideration adjustments		—	—	—	1.2	(1.2)	—	—	(1.2)	(0.01)
Change in financial assets		—	—	—	—	—	122.8	—	(122.8)	(0.90)
Milestone income related to royalty rights		—	—	—	—	—	3.0	—	(3.0)	(0.02)
Separation and reorganization expense		—	—	(7.3)	—	7.3	—	—	7.3	0.05
Impairment charges		—	—	—	(0.9)	0.9	—	—	0.9	0.01
(Gain) loss on divestitures		—	—	—	0.2	(0.2)	(1.1)	—	0.9	0.01
Unusual litigation		—	—	(1.8)	—	1.8	—	—	1.8	0.01
Loss on investment securities		—	—	—	—	—	2.2	—	(2.2)	(0.02)
Restructuring charges and other termination benefits		—	—	(3.4)	2.2	1.2	—	—	1.2	0.01
Non-GAAP tax adjustments*		—	—	—	—	—	—	(89.4)	89.4	0.66
<b>Adjusted</b>		<b>\$ 490.4</b>	<b>\$ 44.4</b>	<b>\$ 250.7</b>	<b>\$ —</b>	<b>\$ 195.3</b>	<b>\$ 30.7</b>	<b>\$ 32.8</b>	<b>\$ 131.8</b>	<b>\$ 0.97</b>
As a % of reported net sales		41.0%	3.7%	21.0%		16.3%	2.6 %	2.7%	11.0%	
Effective tax rate								19.9%		

**Diluted weighted average shares outstanding**

**Reported**

**136.3**

\*The non-GAAP tax adjustments include the following: (1) \$(53.1) million of tax effects of pretax non-GAAP adjustments; (2) \$(34.7) million net impact related to valuation allowances on deferred tax assets commensurate with non-GAAP pre-tax measures; and (3) \$(1.6) million net impact related to regulatory changes.

\*\*Individual pre-tax line item adjustments have not been tax effected, as tax expense on these items are aggregated in the "Non-GAAP tax adjustments" line item.

**TABLE I (CONTINUED)**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**SELECTED CONSOLIDATED INFORMATION**  
(in millions, except per share amounts)  
(unaudited)

Twelve Months Ended December 31, 2019

<b>Consolidated</b>	<b>Net Sales</b>	<b>Gross Profit</b>	<b>R&amp;D Expense</b>	<b>DSG&amp;A Expense</b>	<b>Restructuring, Impairment Charges, and Other Operating Income</b>	<b>Operating Income</b>	<b>Interest, Other, and Change in Financial Assets</b>	<b>Income Tax Expense</b>	<b>Net Income****</b>	<b>Diluted Earnings per Share****</b>
<b>Reported</b>	\$ 4,837.4	\$ 1,773.3	\$ 187.4	\$ 1,166.1	\$ 215.0	\$ 204.8	\$ 33.8	\$ 24.9	\$ 146.1	\$ 1.07
As a % of reported net sales		36.7%	3.9%	24.1%	4.4%	4.2%	0.7%	0.5%	3.0%	
Effective tax rate								14.6%		
<i>Pre-tax adjustments:</i>										
Amortization expense related primarily to acquired intangible assets	\$ —	\$ 191.9	\$ (0.4)	\$ (119.0)	\$ —	\$ 311.3	\$ —	\$ —	\$ 311.3	\$ 2.29
Acquisition and integration-related charges and contingent consideration adjustments	—	5.7	—	(14.6)	1.3	19.0	—	—	19.0	0.14
Restructuring charges and other termination benefits	—	—	—	—	(26.3)	26.3	—	—	26.3	0.19
(Gain) loss on divestitures	—	—	—	3.5	1.6	(5.1)	70.9	—	(76.0)	(0.56)
Ranitidine market withdrawal*	9.2	18.4	—	—	—	18.4	—	—	18.4	0.14
Operating results attributable to held-for-sale business**	(24.1)	(12.1)	(0.5)	(9.4)	—	(2.2)	—	—	(2.2)	(0.02)
Change in financial assets	—	—	—	—	—	—	22.1	—	(22.1)	(0.16)
Asset abandonment	—	—	—	—	(7.1)	7.1	—	—	7.1	0.05
Unusual litigation	—	—	—	(27.2)	—	27.2	—	—	27.2	0.20
Separation and reorganization expense	—	—	—	(17.9)	—	17.9	—	—	17.9	0.13
Impairment charges	—	—	—	—	(184.5)	184.5	—	—	184.5	1.35
Loss on early debt extinguishment	—	—	—	—	—	—	(0.2)	—	0.2	—
(Gain) Loss on investment securities	—	—	—	—	—	—	(4.7)	—	4.7	0.04
Non-GAAP tax adjustments***	—	—	—	—	—	—	—	112.9	(112.9)	(0.83)
<b>Adjusted</b>	<b>\$ 4,822.5</b>	<b>\$ 1,977.2</b>	<b>\$ 186.5</b>	<b>\$ 981.5</b>	<b>\$ —</b>	<b>\$ 809.2</b>	<b>\$ 121.9</b>	<b>\$ 137.8</b>	<b>\$ 549.5</b>	<b>\$ 4.03</b>
As a % of adjusted net sales		41.0%	3.9%	20.4%		16.8%	2.5%	2.9%	11.4%	
Effective tax rate								20.0%		

**Diluted weighted average shares outstanding**

**Reported**

**136.5**

\*Ranitidine market withdrawal includes reversal of recorded returns and inventory write-downs.

\*\*Held-for-sale business includes our now divested animal health business.

\*\*\*The non-GAAP tax adjustments are primarily due to: (1) \$67.5 million tax effects of pretax non-GAAP adjustments that are calculated based upon the specific rate of the applicable jurisdiction of the pretax items and (2) \$43.8 million of valuation allowance releases in the U.S. and Australia.

\*\*\*\*Individual pre-tax line item adjustments have not been tax effected, as tax expense on these items are aggregated in the "Non-GAAP tax adjustments" line item.

**TABLE I (CONTINUED)**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**SELECTED CONSOLIDATED INFORMATION**  
(in millions, except per share amounts)  
(unaudited)

Twelve Months Ended December 31, 2018

<b>Consolidated</b>	<b>Net Sales</b>	<b>Gross Profit</b>	<b>R&amp;D Expense</b>	<b>DSG&amp;A Expense</b>	<b>Restructuring, Impairment Charges, and Other Operating Income</b>	<b>Operating Income</b>	<b>Interest, Other, and Change in Financial Assets</b>	<b>Income Tax Expense</b>	<b>Net Income**</b>	<b>Diluted Earnings per Share**</b>
<b>Reported</b>	<b>\$ 4,731.7</b>	<b>\$ 1,831.5</b>	<b>\$ 218.6</b>	<b>\$ 1,125.8</b>	<b>\$ 250.6</b>	<b>\$ 236.5</b>	<b>\$ (54.1)</b>	<b>\$ 159.6</b>	<b>\$ 131.0</b>	<b>\$ 0.95</b>
As a % of reported net sales		38.7%	4.6%	23.8%	5.3%	5.0%	(1.1)%	3.4%	2.8%	
Effective tax rate								54.9%		
<i>Pre-tax adjustments:</i>										
Amortization expense primarily related to acquired intangible assets		\$ 206.7	\$ (1.0)	\$ (130.9)	\$ —	\$ 338.6	\$ —	\$ —	\$ 338.6	\$ 2.44
Acquisition and integration-related charges and contingent consideration adjustments		—	(50.0)	—	(6.6)	56.6	—	—	56.6	0.41
Separation and reorganization expense		—	—	(13.9)	—	13.9	—	—	13.9	0.10
Milestone income related to royalty rights		—	—	—	—	—	3.0	—	(3.0)	(0.02)
Impairment charges		—	—	—	(224.4)	224.4	—	—	224.4	1.62
Unusual litigation		—	—	(3.2)	—	3.2	—	—	3.2	0.02
Loss on investment securities		—	—	—	—	—	(9.3)	—	9.3	0.07
Restructuring charges and other termination benefits		—	—	(7.4)	(21.0)	28.4	—	—	28.4	0.21
(Gain) loss on divestitures		—	—	3.6	1.4	(5.0)	(2.7)	—	(2.3)	(0.02)
Change in financial assets		—	—	—	—	—	188.7	—	(188.7)	(1.36)
Non-GAAP tax adjustments*		—	—	—	—	—	—	(17.5)	17.5	0.13
<b>Adjusted</b>		<b>\$ 2,038.2</b>	<b>\$ 167.6</b>	<b>\$ 974.0</b>	<b>\$ —</b>	<b>\$ 896.6</b>	<b>\$ 125.6</b>	<b>\$ 142.1</b>	<b>\$ 628.9</b>	<b>\$ 4.55</b>
As a % of reported net sales		43.1%	3.5%	20.6%		18.9%	2.7%	3.0%	13.3%	
Effective tax rate								18.4%		

**Diluted weighted average shares outstanding**

**Reported**

**138.3**

\*The non-GAAP tax adjustments include the following: (1) \$(42.5) million net impact related to valuation allowances on deferred tax assets commensurate with non-GAAP pre-tax measures and (2) \$25.0 million of tax effects of pretax non-GAAP adjustments.

\*\*Individual pre-tax line item adjustments have not been tax effected, as tax expense on these items are aggregated in the "Non-GAAP tax adjustments" line item.

**TABLE II**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**SELECTED SEGMENT INFORMATION**

(in millions)  
(unaudited)

	Three Months Ended December 31, 2019					Three Months Ended December 31, 2018				
	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income
<b>Worldwide Consumer*</b>										
<b>Reported</b>	\$ 1,066.9	\$ 392.5	\$ 34.1	\$ 264.0	\$ 85.6	\$ 946.3	\$ 342.1	\$ 27.1	\$ 272.5	\$ 43.8
As a % of reported net sales		36.8%	3.2%	24.7%	8.0%		36.1%	2.9%	28.8%	4.6%
<i>Pre-tax adjustments:</i>										
Amortization expense related primarily to acquired intangible assets		\$ 26.7	\$ (0.1)	\$ (30.8)	\$ 57.5		\$ 26.4	\$ (0.2)	\$ (30.2)	\$ 56.9
Unusual litigation		—	—	(1.8)	1.8		—	—	(1.8)	1.8
Impairment charges		—	—	—	9.6		—	—	—	0.9
Separation and reorganization expense		—	—	(2.2)	2.2		—	—	(7.3)	7.3
Restructuring charges and other termination benefits		—	—	—	(0.5)		—	—	(3.4)	1.2
(Gain) loss on divestitures		—	—	4.5	(4.6)		—	—	—	—
Acquisition and integration-related charges and contingent consideration adjustments		0.1	—	(1.0)	1.1		—	—	—	—
<b>Adjusted</b>		\$ 419.3	\$ 34.0	\$ 232.7	\$ 152.7		\$ 368.5	\$ 26.9	\$ 229.8	\$ 111.9
As a % of reported net sales		39.3%	3.2%	21.8%	14.3%		38.9%	2.8%	24.3%	11.8%

\*Worldwide Consumer includes the CSCA and CSCI segments in addition to Corporate.

**TABLE II (CONTINUED)**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**SELECTED SEGMENT INFORMATION**

(in millions)  
(unaudited)

	Three Months Ended December 31, 2019					Three Months Ended December 31, 2018				
	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income
<b>Consumer Self-Care Americas</b>										
<b>Reported</b>	<b>\$ 710.5</b>	<b>\$ 233.0</b>	<b>\$ 22.9</b>	<b>\$ 78.5</b>	<b>\$ 130.7</b>	<b>\$ 616.9</b>	<b>\$ 191.1</b>	<b>\$ 15.3</b>	<b>\$ 65.4</b>	<b>\$ 110.2</b>
As a % of reported net sales		32.8%	3.2%	11.1%	18.4%		31.0%	2.5%	10.6%	17.9%
<i>Pre-tax adjustments:</i>										
Amortization expense related primarily to acquired intangible assets		\$ 6.7		\$ (6.5)	\$ 13.2		\$ 5.5		\$ (4.7)	\$ 10.2
Impairment charges		—		—	—		—		—	0.3
(Gain) loss on divestitures		—		—	(0.1)		—		—	—
Separation and reorganization expense		—		0.3	(0.3)		—		—	—
Restructuring charges and other termination benefits		—		—	1.0		—		—	—
Acquisition and integration-related charges and contingent consideration adjustments		0.1		(0.1)	0.3		—		—	—
<b>Adjusted</b>		<b>\$ 239.8</b>		<b>\$ 72.2</b>	<b>\$ 144.8</b>		<b>\$ 196.6</b>		<b>\$ 60.7</b>	<b>\$ 120.7</b>
As a % of reported net sales		33.8%		10.2%	20.4%		31.9%		9.8%	19.6%

	Three Months Ended December 31, 2019					Three Months Ended December 31, 2018				
	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income (Loss)
<b>Consumer Self-Care International</b>										
<b>Reported</b>	<b>\$ 356.4</b>	<b>\$ 159.5</b>	<b>\$ 11.2</b>	<b>\$ 138.6</b>	<b>\$ 1.3</b>	<b>\$ 329.4</b>	<b>\$ 151.0</b>	<b>\$ 11.8</b>	<b>\$ 145.0</b>	<b>\$ (4.8)</b>
As a % of reported net sales		44.8%	3.1%	38.9%	0.4%		45.8%	3.6%	44.0%	(1.5)%
<i>Pre-tax adjustments:</i>										
Amortization expense related primarily to acquired intangible assets		\$ 20.0	\$ (0.1)	\$ (24.2)	\$ 44.3		\$ 20.9	\$ (0.2)	\$ (25.5)	\$ 46.6
Impairment charges		—	—	—	9.6		—	—	—	0.7
Unusual litigation		—	—	—	—		—	—	(1.8)	1.8
Restructuring charges and other termination benefits		—	—	—	(1.1)		—	—	—	(1.7)
(Gain) loss on divestitures		—	—	4.5	(4.5)		—	—	—	—
<b>Adjusted</b>		<b>\$ 179.5</b>	<b>\$ 11.1</b>	<b>\$ 118.9</b>	<b>\$ 49.6</b>		<b>\$ 171.9</b>	<b>\$ 11.6</b>	<b>\$ 117.7</b>	<b>\$ 42.6</b>
As a % of reported net sales		50.4%	3.1%	33.4%	13.9%		52.2%	3.5%	35.7%	12.9%

**TABLE II (CONTINUED)**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**SELECTED SEGMENT INFORMATION**  
(in millions)  
(unaudited)

	Three Months Ended December 31, 2019					Three Months Ended December 31, 2018				
	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income (Loss)	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income
<b>Prescription Pharmaceuticals</b>										
<b>Reported</b>	\$ 255.9	\$ 88.4	\$ 25.3	\$ 24.6	\$ (92.4)	\$ 248.9	\$ 100.9	\$ 17.5	\$ 21.1	\$ 63.7
As a % of reported net sales		34.5%	9.9%	9.6%	(36.1)%		40.6%	7.0%	8.5%	25.6%
<i>Pre-tax adjustments:</i>										
Amortization expense related primarily to acquired intangible assets		\$ 22.1		\$ (0.1)	\$ 22.3		\$ 21.0		\$ (0.2)	\$ 21.1
(Gain) loss on divestitures		—		(0.9)	—		—		—	(0.2)
Restructuring charges and other termination benefits		—		—	0.1		—		—	—
Impairment charges		—		—	132.0		—		—	—
Acquisition and integration-related charges and contingent consideration adjustments		—		—	(0.5)		—		—	(1.2)
<b>Adjusted</b>		\$ 110.5		\$ 23.6	\$ 61.5		\$ 121.9		\$ 20.9	\$ 83.4
As a % of reported net sales		43.2%		9.2%	24.0 %		49.0%		8.4%	33.5%

**TABLE II (CONTINUED)**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**SELECTED SEGMENT INFORMATION**

(in millions)  
(unaudited)

	Twelve Months Ended December 31, 2019					Twelve Months Ended December 31, 2018				
	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income
<b>Worldwide Consumer*</b>										
<b>Reported</b>	\$ 3,869.9	\$ 1,438.4	\$ 118.7	\$ 1,074.9	\$ 202.2	\$ 3,810.9	\$ 1,457.6	\$ 154.6	\$ 1,037.3	\$ 21.9
As a % of reported net sales		37.2%	3.1%	27.8%	5.2%		38.2%	4.1%	27.2%	0.6%
<i>Pre-tax adjustments:</i>										
Amortization expense related primarily to acquired intangible assets	—	104.7	(0.4)	(118.5)	223.6	—	123.6	(1.0)	(130.4)	255.0
Separation and reorganization expense	—	—	—	(17.2)	17.2	—	—	—	(13.9)	13.9
Unusual litigation	—	—	—	(27.2)	27.2	—	—	—	(3.2)	3.2
Impairment charges	—	—	—	—	13.8	—	—	—	—	224.4
Asset abandonment	—	—	—	—	7.1	—	—	—	—	—
(Gain) loss on divestitures	—	—	—	4.4	(4.5)	—	—	—	3.6	(3.6)
Operating results attributable to held-for-sale business**	(24.1)	(12.1)	(0.5)	(9.4)	(2.2)	—	—	—	—	—
Restructuring charges and other termination benefits	—	—	—	—	26.0	—	—	—	(7.4)	28.2
Ranitidine market withdrawal***	9.2	18.4	—	—	18.4	—	—	—	—	—
Acquisition and integration-related charges and contingent consideration adjustments	—	5.7	—	(14.6)	16.2	—	—	(50.0)	—	48.6
<b>Adjusted</b>	3,855.0	1,555.1	117.8	892.4	545.0	1,581.2	103.6	103.6	886.0	591.6
As a % of adjusted net sales (2019) / As a % of reported net sales (2018)		40.3%	3.1%	23.1%	14.1%		41.5%	2.7%	23.2%	15.5%

\*Worldwide Consumer includes the CSCA and CSCI segments in addition to Corporate.

\*\*Held-for-sale business includes our now divested animal health business.

\*\*\*Ranitidine market withdrawal includes reversal of recorded returns and inventory write-downs.



**TABLE II (CONTINUED)**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**SELECTED SEGMENT INFORMATION**  
(in millions)  
(unaudited)

	Twelve Months Ended December 31, 2019					Twelve Months Ended December 31, 2018				
	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income
<b>Consumer Self-Care Americas</b>										
<b>Reported</b>	\$ 2,487.7	\$ 798.9	\$ 76.3	\$ 298.9	\$ 414.0	\$ 2,411.6	\$ 789.0	\$ 110.7	\$ 282.3	\$ 174.4
As a % of reported net sales		32.1%	3.1%	12.0%	16.6%		32.7%	4.6%	11.7%	7.2%
<i>Pre-tax adjustments:</i>										
Amortization expense primarily related to acquired intangible assets	\$ —	\$ 23.8	\$ —	\$ (22.4)	\$ 46.2	\$ 37.2	\$ —	\$ (18.9)	\$ —	\$ 56.0
Separation and reorganization expense	—	—	—	(0.4)	0.4	—	—	—	—	—
Unusual litigation	—	—	—	(1.3)	1.3	—	—	—	—	—
Asset abandonment	—	—	—	—	7.1	—	—	—	—	—
Impairment charges	—	—	—	—	4.1	—	—	—	—	222.6
(Gain) loss on divestitures	—	—	—	—	(0.1)	—	—	—	—	—
Operating results attributable to held-for-sale business**	(24.1)	(12.1)	(0.5)	(9.4)	(2.2)	—	—	—	—	—
Restructuring charges and other termination benefits	—	—	—	—	2.7	—	—	—	—	0.4
Ranitidine market withdrawal*	7.4	15.5	—	—	15.5	—	—	—	—	—
Acquisition and integration-related charges and contingent consideration adjustments	—	3.6	—	1.0	(1.5)	—	(50.0)	—	—	48.6
<b>Adjusted</b>	\$ 2,471.0	\$ 829.7	\$ 75.8	\$ 266.4	\$ 487.5	\$ 826.2	\$ 60.7	\$ 263.4	\$ —	\$ 502.0
As a % of adjusted net sales (2019) / As a % of reported net sales (2018)		33.6%	3.1%	10.8%	19.7%		34.3%	2.5%	10.9%	20.8%

\*Ranitidine market withdrawal includes reversal of recorded returns and inventory write-downs.

\*\*Held-for-sale business includes our now divested animal health business.

**TABLE II (CONTINUED)**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**SELECTED SEGMENT INFORMATION**  
(in millions)  
(unaudited)

	Twelve Months Ended December 31, 2019					Twelve Months Ended December 31, 2018				
	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income
<b>Consumer Self-Care International</b>										
<b>Reported</b>	<b>\$ 1,382.2</b>	<b>\$ 639.5</b>	<b>\$ 42.4</b>	<b>\$ 558.1</b>	<b>\$ 19.6</b>	<b>\$ 1,399.3</b>	<b>\$ 668.7</b>	<b>\$ 43.9</b>	<b>\$ 598.8</b>	<b>\$ 6.8</b>
As a % of reported net sales		46.3%	3.1%	40.4%	1.4%		47.8%	3.1%	42.8%	0.5%
<i>Pre-tax adjustments:</i>										
Amortization expense primarily related to acquired intangible assets	\$ —	\$ 80.9	\$ (0.4)	\$ (96.2)	\$ 177.5	\$ 86.4	\$ (1.0)	\$ (111.5)	\$ 198.9	
Impairment charges	—	—	—	—	9.7	—	—	—	1.8	
Restructuring charges and other termination benefits	—	—	—	—	9.7	—	—	—	17.4	
Unusual litigation	—	—	—	(0.3)	0.3	—	—	(3.2)	3.2	
Ranitidine market withdrawal*	1.8	2.9	—	—	2.9	—	—	—	—	
(Gain) loss on divestitures	—	—	—	4.4	(4.4)	—	—	—	—	
Acquisition and integration-related charges and contingent consideration adjustments	—	2.1	—	—	2.1	—	—	—	—	
<b>Adjusted</b>	<b>\$ 1,384.0</b>	<b>\$ 725.4</b>	<b>\$ 42.0</b>	<b>\$ 466.0</b>	<b>\$ 217.4</b>	<b>\$ 755.1</b>	<b>\$ 42.9</b>	<b>\$ 484.1</b>	<b>\$ 228.1</b>	
As a % of adjusted net sales (2019) / As a % of reported net sales (2018)		52.4%	3.0%	33.7%	15.7%		54.0%	3.1%	34.6%	16.3%

\*Ranitidine market withdrawal includes reversal of recorded returns and inventory write-downs.

**TABLE II (CONTINUED)**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**SELECTED SEGMENT INFORMATION**  
(in millions)  
(unaudited)

	Twelve Months Ended December 31, 2019					Twelve Months Ended December 31, 2018				
	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income	Net Sales	Gross Profit	R&D Expense	DSG&A Expense	Operating Income
<b>Prescription Pharmaceuticals</b>										
<b>Reported</b>	\$ 967.5	\$ 334.9	\$ 68.7	\$ 91.2	\$ 2.6	\$ 920.8	\$ 373.9	\$ 64.0	\$ 88.5	\$ 214.6
As a % of reported net sales		34.6%	7.1%	9.4%	0.3%		40.6%	6.9%	9.6%	23.3%
<i>Pre-tax adjustments:</i>										
Amortization expense primarily related to acquired intangible assets		\$ 87.2		\$ (0.5)	\$ 87.7		\$ 83.1		\$ (0.5)	\$ 83.6
Separation and reorganization expense		—		(0.7)	0.7		—		—	—
(Gain) loss on divestitures		—		(0.9)	(0.6)		—		—	(1.4)
Restructuring charges and other termination benefits		—		—	0.3		—		—	0.2
Impairment charges		—		—	170.7		—		—	—
Acquisition and integration-related charges and contingent consideration adjustments		—		—	2.8		—		—	8.0
<b>Adjusted</b>		\$ 422.1		\$ 89.1	\$ 264.2		\$ 457.0		\$ 88.0	\$ 305.0
As a % of reported net sales		43.6%		9.2%	27.3%		49.6%		9.6%	33.1%

**TABLE III**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**ADJUSTED NET SALES GROWTH - SELECTED SEGMENTS**  
(in millions)  
(unaudited)

	Three Months Ended		Total Change	FX Change	Constant Currency Change
	December 31, 2019	December 31, 2018			
<b>Net sales</b>					
Consolidated	\$ 1,322.8	\$ 1,195.2	10.7%	0.6%	11.3%
CSCA	\$ 710.5	\$ 616.9	15.2%	(0.1)%	15.1%
CSCI	\$ 356.4	\$ 329.4	8.2%	2.8%	11.0%
RX	\$ 255.9	\$ 248.9	2.8%	(0.6)%	2.2%
Consolidated	\$ 1,322.8	\$ 1,195.2			
Less: animal health	—	(15.3)			
Less: infant foods	—	(7.0)			
Consolidated net sales as so adjusted	\$ 1,322.8	\$ 1,172.9	12.8%	0.6%	13.4%
Worldwide consumer					
CSCA	\$ 710.5	\$ 616.9			
CSCI	356.4	329.4			
Worldwide consumer	\$ 1,066.9	\$ 946.3			
Less: animal health	—	(15.3)			
Less: infant foods	—	(7.0)			
Worldwide Consumer net sales as so adjusted	\$ 1,066.9	\$ 924.0	15.5%	0.9%	16.4%
CSCA	\$ 710.5	\$ 616.9			
Less: animal health	—	(15.3)			
Less: infant foods	—	(7.0)			
CSCA net sales as so adjusted	\$ 710.5	\$ 594.6	19.5%	(0.1)%	19.4%
Less: Ranir	(52.2)	—			
Organic CSCA net sales as so adjusted	\$ 658.3	\$ 594.6	10.7%	(0.1)%	10.6%
CSCI	\$ 356.4	\$ 329.4			
Less: Ranir	(22.2)	—			
Organic CSCI net sales as so adjusted	\$ 334.2	\$ 329.4	1.5%	2.8%	4.3%

**TABLE III (CONTINUED)**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**ADJUSTED NET SALES GROWTH - SELECTED SEGMENTS**  
(in millions)  
(unaudited)

	<b>Three Months Ended</b>		<b>\$ Change</b>	<b>% Change</b>
	<b>December 31, 2019</b>	<b>December 31, 2018</b>		
Nutrition category	\$ 110.1	\$ 97.9		
Less: infant foods	—	(7.0)		
Nutrition category net sales as so adjusted	\$ 110.1	\$ 90.9	\$ 19.2	21.1%
CSCA net sales as so adjusted	\$ 710.5	\$ 594.6	\$ 115.9	
Nutrition category increase as a percentage of growth in CSCA adjusted net sales		16.6%		

**TABLE III (CONTINUED)**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**ADJUSTED NET SALES GROWTH - SELECTED SEGMENTS**  
(in millions)  
(unaudited)

	<b>Twelve Months Ended</b>				
	<b>December 31, 2019</b>	<b>December 31, 2018</b>	<b>Total Change</b>	<b>FX Change</b>	<b>Constant Currency Change</b>
<b>Net sales</b>					
RX	\$ 967.5	\$ 920.8	5.1%	(0.1)%	5.0%
Worldwide Consumer					
CSCA	\$ 2,487.7	\$ 2,411.6			
CSCI	1,382.2	1,399.3			
Total Worldwide Consumer	\$ 3,869.9	\$ 3,810.9	1.5%		
Plus: Ranitidine market withdrawal*	9.2	—			
Less: animal health	(43.7)	(93.9)			
Less: infant foods	(6.1)	(34.1)			
Worldwide Consumer net sales as so adjusted	\$ 3,829.3	\$ 3,682.9	4.0%	2.3%	6.3%
Less: Ranir	(151.4)	—			
Organic Worldwide Consumer net sales as so adjusted	\$ 3,677.9	\$ 3,682.9	(0.1)%	2.3%	2.2%
	<b>Six Months Ended</b>				
	<b>December 31, 2019</b>	<b>December 31, 2018</b>	<b>Total Change</b>	<b>FX Change</b>	<b>Constant Currency Change</b>
<b>Net sales</b>					
Worldwide Consumer					
CSCA	\$ 1,323.8	\$ 1,213.1			
CSCI	703.9	663.6			
Total Worldwide Consumer	\$ 2,027.7	\$ 1,876.7			
Plus: Ranitidine market withdrawal*	9.2	—			
Less: animal health	(1.8)	(35.7)			
Less: infant foods	—	(15.1)			
Worldwide Consumer net sales as so adjusted	\$ 2,035.1	\$ 1,825.9			
Less: Ranir	(151.4)	—			
Organic Worldwide Consumer net sales as so adjusted	\$ 1,883.7	\$ 1,825.9	3.2%	1.5%	4.7%

\*Ranitidine market withdrawal includes reversal of recorded returns and inventory write-downs.

**TABLE IV**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**ADJUSTED PROFIT MEASURE GROWTH - SELECTED**  
(in millions)  
(unaudited)

	<u>Three Months Ended</u>		<u>Total Change</u>	<u>FX Change</u>	<u>Constant Currency Change</u>
	<u>December 31, 2019</u>	<u>December 31, 2018</u>			
<b>Adjusted operating income</b>					
CSCI	49.6	42.6	16.4%	1.9%	18.3%
<b>Adjusted gross profit</b>					
Worldwide Consumer					
CSCA	\$ 239.8	\$ 196.6			
CSCI	179.5	171.9			
Worldwide Consumer adjusted gross profit	\$ 419.3	\$ 368.5			
Less: animal health	—	(7.2)			
Less: infant foods	—	(1.0)			
Worldwide Consumer adjusted gross profit less exited businesses	\$ 419.3	\$ 360.3	16.4%	1.1%	17.5%

**TABLE IV (CONTINUED)**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
**ADJUSTED PROFIT MEASURE GROWTH - SELECTED**  
(in millions)  
(unaudited)

	<b>Twelve Months Ended</b>		<b>Total Change</b>	<b>FX Change</b>	<b>Constant Currency Change</b>
	<b>December 31, 2019</b>	<b>December 31, 2018</b>			
<b>Adjusted gross profit</b>					
Worldwide Consumer					
CSCA	\$ 829.7	\$ 826.2			
CSCI	725.4	755.1			
Unallocated	\$ —	\$ (0.1)			
Worldwide Consumer adjusted gross profit	\$ 1,555.1	\$ 1,581.2			
Less: animal health	(10.4)	(48.0)			
Less: infant foods	(0.4)	(5.7)			
Worldwide Consumer adjusted gross profit less exited businesses	\$ 1,544.3	\$ 1,527.5	1.1%	3.0%	4.1%
<b>Adjusted operating income</b>					
Worldwide consumer					
CSCA	\$ 487.5	\$ 502.0			
CSCI	217.4	228.1			
Unallocated	(159.9)	(138.5)			
Worldwide Consumer adjusted operating income	\$ 545.0	\$ 591.6			
Less: animal health	(2.9)	(13.8)			
Less: Infant foods	(0.4)	(5.7)			
Worldwide Consumer adjusted operating income less exited businesses	\$ 541.7	\$ 572.1	(5.3)%	2.3%	(3.0)%



**TABLE V**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
(in millions, except per share amounts)  
(unaudited)

	<b>Three Months Ended</b>		
	<b>December 31, 2019</b>	<b>December 31, 2018</b>	<b>Total Change</b>
<b>Consolidated adjusted EPS</b>	\$ 1.06	\$ 0.97	9.3%
<b>Adjusted gross profit</b>			
Worldwide Consumer	\$ 419.3	\$ 368.5	13.8%
CSCA	\$ 239.8	\$ 196.6	22.0%
CSCI	\$ 179.5	\$ 171.9	4.5%
RX	\$ 110.5	\$ 121.9	(9.4)%
<b>Adjusted gross margin</b>			
Worldwide Consumer	39.3%	38.9%	40 bps
CSCA	33.8%	31.9%	190 bps
CSCI	50.4%	52.2%	(180) bps
RX	43.2%	49.0%	(580) bps
<b>Adjusted operating income</b>			
Worldwide Consumer	\$ 152.7	\$ 111.9	36.5%
CSCA	\$ 144.8	\$ 120.7	20.0%
CSCI	\$ 49.6	\$ 42.6	16.4%
RX	\$ 61.5	\$ 83.4	(26.3)%
<b>Adjusted operating margin</b>			
Worldwide Consumer	14.3%	11.8%	250 bps
CSCA	20.4%	19.6%	80 bps
CSCI	13.9%	12.9%	100 bps
RX	24.0%	33.5%	(950) bps
	<b>Twelve Months Ended</b>		
	<b>December 31, 2019</b>	<b>December 31, 2018</b>	<b>Total Change</b>
<b>Adjusted gross margin</b>			
RX	43.6%	49.6%	(600) bps

**TABLE VI**  
**PERRIGO COMPANY PLC**  
**DISAGGREGATION OF REVENUE BY QUARTER**  
(in millions)  
(unaudited)

	Three Months Ended			
	March 30, 2019	June 29, 2019	September 28, 2019	December 31, 2019
CSCA <sup>(1)</sup>				
Upper respiratory	\$ 132.8	\$ 121.2	\$ 123.4	\$ 137.8
Digestive health	102.3	106.3	85.0	120.3
Nutrition	99.6	85.9	97.1	111.8
Pain and sleep-aids	91.3	91.3	89.4	111.6
Healthy lifestyle	76.0	86.1	87.9	102.4
Skincare and personal hygiene	45.5	45.8	45.4	46.2
Oral self-care	—	—	54.2	52.2
Animal health	19.6	22.3	1.8	—
Vitamins, minerals, and supplements	6.3	6.2	6.2	9.9
Other CSCA <sup>(2)</sup>	8.4	17.0	22.9	18.3
Total CSCA	<u>\$ 581.8</u>	<u>\$ 582.1</u>	<u>\$ 613.3</u>	<u>\$ 710.5</u>
CSCI				
Skincare and personal hygiene	\$ 101.9	\$ 105.7	\$ 88.9	\$ 75.1
Upper respiratory	71.9	49.9	72.1	82.9
Vitamins, minerals, and supplements	45.8	41.1	46.2	47.1
Healthy lifestyle	47.3	48.7	38.2	39.6
Pain and sleep-aids	40.4	39.4	40.5	47.6
Oral self-care	1.6	1.8	24.3	23.5
Digestive health	7.2	6.8	5.3	7.8
Other CSCI <sup>(3)</sup>	34.7	34.1	32.0	32.8
Total CSCI	<u>\$ 350.8</u>	<u>\$ 327.5</u>	<u>\$ 347.5</u>	<u>\$ 356.4</u>

(1) Includes net sales from our OTC contract manufacturing business.

(2) Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

(3) Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

**TABLE VII**  
**PERRIGO COMPANY PLC**  
**RECONCILIATION OF NON-GAAP MEASURES**  
(in millions)  
(unaudited)

	<u>Twelve Months Ended</u>	
	<u>December 31,</u>	
	<u>2019</u>	
Operating cash flow	\$	387.8
Adjusted net income	\$	549.5
Cash conversion ratio		71%